|
rs2046210
|
|
|
0.020 |
GeneticVariation |
BEFREE |
With the exception of rs2046210 at 6q25.1, the seven other SNPs showed a stronger association with ER-positive than ER-negative cancer.
|
23535825 |
2013 |
|
rs3020450
|
|
|
0.020 |
GeneticVariation |
BEFREE |
With regard to genotype frequency, allele frequency, allele positivity or haplotype frequency of SNPs rs2987983, rs3020449 and rs3020450 we did not observe a significant difference between the cancer and the control group.
|
24881814 |
2014 |
|
rs3020449
|
|
|
0.010 |
GeneticVariation |
BEFREE |
With regard to genotype frequency, allele frequency, allele positivity or haplotype frequency of SNPs rs2987983, rs3020449 and rs3020450 we did not observe a significant difference between the cancer and the control group.
|
24881814 |
2014 |
|
rs4778889
|
|
|
0.030 |
GeneticVariation |
BEFREE |
With all studies involved, results showed no statistically significant association between IL-16 rs4778889 T/C polymorphism and cancer risk (CC vs. CT+TT: OR=0.74, 95%CI: 0.55-1.02, Ph=0.15; CC+CT vs. TT: OR=0.89, 95%CI: 0.72-1.10, Ph =0.03; CC vs. TT: OR=0.73, 95%CI: 0.53- 1.00, Ph =0.08; CT vs. TT: OR=0.91, 95%CI: 0.79-1.05, Ph =0.08; C vs. T: OR=0.89, 95%CI: 0.74-1.07, Ph =0.02).
|
24568499 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
With advances in RAF inhibitors and second-generation inhibitors including encorafenib and vemurafenib, which have been approved for treating BRAF-V600E malignancies, the combinatorial therapeutic strategies of RAF inhibitors elicit remarkable responses in patients with BRAF-V600E mCRC.
|
30122982 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
With advances in RAF inhibitors and second-generation inhibitors including encorafenib and vemurafenib, which have been approved for treating BRAF-V600E malignancies, the combinatorial therapeutic strategies of RAF inhibitors elicit remarkable responses in patients with BRAF-V600E mCRC.
|
30122982 |
2018 |
|
rs397517132
|
|
|
0.090 |
GeneticVariation |
BEFREE |
With advances in RAF inhibitors and second-generation inhibitors including encorafenib and vemurafenib, which have been approved for treating BRAF-V600E malignancies, the combinatorial therapeutic strategies of RAF inhibitors elicit remarkable responses in patients with BRAF-V600E mCRC.
|
30122982 |
2018 |
|
rs895819
|
|
|
0.100 |
GeneticVariation |
BEFREE |
With a novel statistic, Cross phenotype meta-analysis (CPMA) of the association of MirSNPs with multiple phenotypes indicated rs2910164 C (P = 1.11E-03), rs2043556 C (P = 0.0165), rs6505162 C (P = 2.05E-03) and rs895819 (P = 0.0284) were associated with a significant overall risk of cancer.
|
24413317 |
2014 |
|
rs6505162
|
|
|
0.060 |
GeneticVariation |
BEFREE |
With a novel statistic, Cross phenotype meta-analysis (CPMA) of the association of MirSNPs with multiple phenotypes indicated rs2910164 C (P = 1.11E-03), rs2043556 C (P = 0.0165), rs6505162 C (P = 2.05E-03) and rs895819 (P = 0.0284) were associated with a significant overall risk of cancer.
|
24413317 |
2014 |
|
rs2043556
|
|
|
0.020 |
GeneticVariation |
BEFREE |
With a novel statistic, Cross phenotype meta-analysis (CPMA) of the association of MirSNPs with multiple phenotypes indicated rs2910164 C (P = 1.11E-03), rs2043556 C (P = 0.0165), rs6505162 C (P = 2.05E-03) and rs895819 (P = 0.0284) were associated with a significant overall risk of cancer.
|
24413317 |
2014 |
|
rs2910164
|
|
|
0.100 |
GeneticVariation |
BEFREE |
With a novel statistic, Cross phenotype meta-analysis (CPMA) of the association of MirSNPs with multiple phenotypes indicated rs2910164 C (P = 1.11E-03), rs2043556 C (P = 0.0165), rs6505162 C (P = 2.05E-03) and rs895819 (P = 0.0284) were associated with a significant overall risk of cancer.
|
24413317 |
2014 |
|
rs151227402
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing of cancer cells with acquired resistance to ONC201 revealed a <i>de novo</i> Q366R mutation in the DRD5 gene.
|
30559168 |
2019 |
|
rs371217738
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing of cancer cells with acquired resistance to ONC201 revealed a <i>de novo</i> Q366R mutation in the DRD5 gene.
|
30559168 |
2019 |
|
rs771246666
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing of cancer cells with acquired resistance to ONC201 revealed a <i>de novo</i> Q366R mutation in the DRD5 gene.
|
30559168 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While they produce dramatic responses in a subset of patients-primarily those with activating EGFR mutations-remissions are typically limited to several months due to acquired drug resistance, frequently associated with the secondary T790M mutation in EGFR.In this issue of Cancer Cell, Li et al. report that an irreversible EGFR kinase inhibitor, HKI-272, had limited activity in a mouse lung cancer model driven by an EGFR mutant harboring T790M and an activating mutation.
|
17613432 |
2007 |
|
rs3761548
|
|
|
0.020 |
GeneticVariation |
BEFREE |
While no significant results were observed in overall and breast cancer groups for rs3761548 (A/C) polymorphisms, the pooled data showed an elevated risk of cancer in variant AA genotypes and A allele for Chinese population (AA vs. AC+CC: OR = 1.61, 95% CI = 1.09, 2.39; AA vs. CC: OR = 1.74, 95% CI = 1.05, 2.89; A vs. C: OR = 1.34, 95% CI = 1.00, 1.78).
|
30782783 |
2019 |
|
rs439680
|
|
|
0.010 |
GeneticVariation |
BEFREE |
While no association between SNPs and small cell lung cancer was shown, the rs10937405 and rs439680 associations were significant for squamous cancer (respective P-values, 0.0022 and 0.02).
|
21610222 |
2011 |
|
rs10937405
|
|
|
0.010 |
GeneticVariation |
BEFREE |
While no association between SNPs and small cell lung cancer was shown, the rs10937405 and rs439680 associations were significant for squamous cancer (respective P-values, 0.0022 and 0.02).
|
21610222 |
2011 |
|
rs3746444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Whereas, rs3746444 G allele was a risk factor in Chinese population, and the association varied from different cancer types.
|
23750236 |
2013 |
|
rs3803185
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
rs34301344
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
rs755100942
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
rs147120792
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
rs1190999960
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When the role of SCF<sup>Skp2/Cks1</sup>-mediated p27 ubiquitination in cancer was specifically tested by p27 Thr187-to-Ala knockin (p27T187A KI), it was found dispensable for Kras<sup>G12D</sup>-induced lung tumorigenesis but essential for Rb1-deficient pituitary tumorigenesis.
|
27181203 |
2017 |
|
rs1250394819
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When the role of SCF<sup>Skp2/Cks1</sup>-mediated p27 ubiquitination in cancer was specifically tested by p27 Thr187-to-Ala knockin (p27T187A KI), it was found dispensable for Kras<sup>G12D</sup>-induced lung tumorigenesis but essential for Rb1-deficient pituitary tumorigenesis.
|
27181203 |
2017 |